Imagine if you could get the detailed 'sugar-mapping' of a cancer scan without the radiation risks of a PET scan. This technology uses a special version of sugar tagged with heavy hydrogen (deuterium) that acts like a beacon for MRI machines. It allows doctors to see where tumors are hiding using standard MRI equipment, making it safe for children and pregnant women.
Current cancer staging via FDG-PET is limited by ionizing radiation, restricting the number of scans per year and preventing use in children and pregnant women.
A deuterated-2-deoxy-D-glucose (DDG) contrast agent and the corresponding MRI acquisition software/hardware for 3T scanners.
If you are a medical device company dealing with the need for more functional imaging capabilities — this project developed a deuterium MRI acquisition scheme that enables PET-like images on 3T scanners. This allows your hardware to perform cancer detection without requiring significant hardware changes.
If you are a chemical manufacturer dealing with the demand for safer diagnostic tracers — this project developed a deuterated-2-deoxy-D-glucose (DDG) agent. This stable isotope chemistry provides a non-ionizing alternative to FDG-PET for tumor staging and monitoring.
If you are a clinic dealing with the limitation of only 2-3 PET scans per year per patient due to radiation — this project developed a DDG-MRI technique. This allows for more frequent treatment monitoring and expands your patient base to include children and pregnant women.
Based on available project data, the DDG-MRI technology is expected to cost the same as a PET scan.
Yes, the technology is designed for clinical MRI 3T scanners and does not require significant hardware changes or alterations to the MRI suite workflow.
The project includes a specific objective to develop a strategy for the commercialization of the DDG contrast agent and the associated MRI technology.
The project is actively studying the human regulatory aspects of DDG to ensure it can be used safely in clinical settings.
The expected scan time for the DDG-MRI technique is about 2 minutes.
The consortium shows a strong commercial orientation with a 43% industry ratio, consisting of 3 industrial partners and 4 universities across 6 countries. The presence of SMEs and large medical organizations like Hadassah suggests a balanced pipeline from academic research to industrial application.
Contact Hadassah Medical Organization in Israel
Contact us to explore licensing opportunities for the DDG contrast agent.
